H. Perez
Director/Board Member bij Presidio Pharmaceuticals, Inc.
Profiel
H.
Daniel Perez is the founder of Naia Rare Diseases LLC, which was founded in 2014.
He held the title of Chairman & Chief Executive Officer at Naia Rare Diseases LLC.
Currently, Dr. Perez is the Director at Presidio Pharmaceuticals, Inc. and the Professor at The University of California, San Francisco.
In the past, he was the President & Chief Executive Officer at Berlex Biosciences from 1993 to 2006.
He also served as the Chairman at Accelerated Pharma, Inc. from 2015 to 2016, Independent Director at Cleveland BioLabs, Inc. from 2006 to 2011, Director at Celtaxsys, Inc. from 2011 to 2013, Director at Hyperion Therapeutics, Inc., and Venture Partner at Bay City Capital LLC.
Dr. Perez obtained a doctorate degree from Universidad de Buenos Aires and an undergraduate degree from Universidad Mariano Egaña.
Actieve functies van H. Perez
| Bedrijven | Functie | Begin |
|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | - |
Presidio Pharmaceuticals, Inc.
 Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Eerdere bekende functies van H. Perez
| Bedrijven | Functie | Einde |
|---|---|---|
| ACCELERATED PHARMA INC | Chairman | 01-02-2016 |
| STATERA BIOPHARMA, INC. | Director/Board Member | - |
| Berlex Biosciences | Chief Executive Officer | 01-01-2006 |
Naia Rare Diseases LLC
 Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Chief Executive Officer | - |
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Chairman | - |
Opleiding van H. Perez
| Universidad de Buenos Aires | Doctorate Degree |
| Universidad Mariano Egaña | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Cleveland BioLabs, Inc.
 Cleveland BioLabs, Inc. Pharmaceuticals: MajorHealth Technology Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. It focuses on oncology and acute radiation syndrome. It offers Entolimod, Mobilan, CBL0137, and SA-702. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY. | Health Technology |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
Accelerated Pharma, Inc.
 Accelerated Pharma, Inc. Medical SpecialtiesHealth Technology Accelerated Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in development of pre-existing pharmaceutical products for the treatment of various cancer indications. It offers a platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications under the Picoplatin brand. The company was founded by Michael Fonstein, Ekaterina E. Nikolaevskaya and Dmitry Prudnikov in May 2014 and is headquartered in Westport, CT. | Health Technology |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
Presidio Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc. BiotechnologyHealth Technology Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA. | Health Technology |
| Berlex Biosciences | |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
